Can a common acid reflux drug keep kids Ulcer-Free?
NCT ID NCT03553563
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 3 study tested the drug D961H (esomeprazole) in 50 Japanese children to see if it can prevent reflux esophagitis from coming back and stop stomach or duodenal ulcers from recurring in kids taking NSAIDs or low-dose aspirin. Children took the drug for up to 52 weeks, and researchers tracked relapses and side effects. The goal is to find a safe, effective long-term maintenance dose for pediatric patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Esomeprazole (D961H)
What this could lead to
If successful, this could confirm a safe and effective maintenance dose of esomeprazole for Japanese children to prevent relapse of reflux esophagitis and stomach ulcers.
What could go wrong
This is a small, completed Phase 3 study in Japanese children only, so results may not apply to other populations. Long-term safety data is limited to 52 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ULCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Bunkyō City, 113-8431, Japan
-
Research Site
Bunkyō City, 113-8519, Japan
-
Research Site
Fuji-shi, 417-8567, Japan
-
Research Site
Izumi-shi, 594-1101, Japan
-
Research Site
Kagoshima, 890-8520, Japan
-
Research Site
Kanazawa, 920-8641, Japan
-
Research Site
Maebashi, 371-8511, Japan
-
Research Site
Matsumoto-shi, 390-8621, Japan
-
Research Site
Okayama, 701-1192, Japan
-
Research Site
Sakaishi, 593-8304, Japan
-
Research Site
Setagaya-ku, 157-8535, Japan
-
Research Site
Shinjuku-ku, 160-0023, Japan
-
Research Site
Takatsuki-shi, 569-8686, Japan
-
Research Site
Yokohama, 230-8765, Japan
-
Research Site
Yokohama, 232 8555, Japan